PT - JOURNAL ARTICLE AU - Benussi, Alberto AU - Pilotto, Andrea AU - Premi, Enrico AU - Libri, Ilenia AU - Giunta, Marcello AU - Agosti, Chiara AU - Alberici, Antonella AU - Baldelli, Enrico AU - Benini, Matteo AU - Bonacina, Sonia AU - Brambilla, Laura AU - Caratozzolo, Salvatore AU - Cortinovis, Matteo AU - Costa, Angelo AU - Piccinelli, Stefano Cotti AU - Cottini, Elisabetta AU - Cristillo, Viviana AU - Delrio, Ilenia AU - Filosto, Massimiliano AU - Gamba, Massimo AU - Gazzina, Stefano AU - Gilberti, Nicola AU - Gipponi, Stefano AU - Imarisio, Alberto AU - Invernizzi, Paolo AU - Leggio, Ugo AU - Leonardi, Matilde AU - Liberini, Paolo AU - Locatelli, Martina AU - Masciocchi, Stefano AU - Poli, Loris AU - Rao, Renata AU - Risi, Barbara AU - Rozzini, Luca AU - Scalvini, Andrea AU - di Cola, Francesca Schiano AU - Spezi, Raffaella AU - Vergani, Veronica AU - Volonghi, Irene AU - Zoppi, Nicola AU - Borroni, Barbara AU - Magoni, Mauro AU - Pezzini, Alessandro AU - Padovani, Alessandro TI - Clinical characteristics and outcomes of inpatients with neurological disease and COVID-19 AID - 10.1101/2020.04.28.20082735 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.28.20082735 4099 - http://medrxiv.org/content/early/2020/05/05/2020.04.28.20082735.short 4100 - http://medrxiv.org/content/early/2020/05/05/2020.04.28.20082735.full AB - Objective To report the clinical and laboratory characteristics, as well as treatment and clinical outcomes of patients admitted for neurological diseases with and without COVID-19.Methods In this retrospective, single center cohort study, we included all adult inpatients with confirmed COVID-19, admitted to a Neuro-COVID Unit from February 21, 2020, who had been discharged or died by April 5, 2020. Demographic, clinical, treatment, and laboratory data were extracted from medical records and compared (FDR-corrected) to those of neurological patients without COVID-19 admitted in the same period.Results 173 patients were included in this study, of whom 56 were positive for COVID-19 while 117 were negative for COVID-19. Patients with COVID-19 were older, had a different distribution regarding admission diagnoses, including cerebrovascular disorders, and had a higher quick Sequential Organ Failure Assessment (qSOFA) score on admission (all p<0.05). In-hospital mortality rates and incident delirium were significantly higher in the COVID-19 group (all p<0.005). COVID-19 and non-COVID patients with stroke had similar baseline characteristics but patients with COVID-19 had higher modified Rankin scale scores at discharge, with a significantly lower number of patients with a good outcome (all p<0.001).In patients with COVID-19, multivariable regressions showed increasing odds of in-hospital death associated with higher qSOFA scores (odds ratio 4.47, 95% CI 1.21-16.5; p=0.025), lower platelet count (0.98, 0.97-0.99; p=0.005) and higher lactate dehydrogenase (1.01, 1.00-1.03; p=0.009) on admission.Conclusions COVID-19 patients admitted with neurological disease, including stroke, have a significantly higher in-hospital mortality, incident delirium and higher disability than patients without COVID-19.Competing Interest StatementA. Benussi, A. Pilotto, E. Premi, I. Libri, M. Giunta, C. Agosti, A. Alberici, E. Baldelli, M. Benini, S. Bonacina, L. Brambilla, S. Caratozzolo, M. Cortinovis, A. Costa, S. Cotti Piccinelli, E. Cottini, V. Cristillo, I. Delrio, M. Gamba, S. Gazzina, N. Gilberti, S. Gipponi, A. Imarisio, P. Invernizzi, U. Leggio, M. Leonardi, P. Liberini, M. Locatelli, S. Masciocchi, L. Poli, R. Rao, B. Risi, L. Rozzini, A. Scalvini, F. Schiano di Cola, R. Spezi, V. Vergani, I. Volonghi, N. Zoppi, B. Borroni, M. Magoni, A. Pezzini report no disclosures relevant to the manuscript. A. Padovani is consultant and served on the scientific advisory board of GE Healthcare, Eli-Lilly and Actelion Ltd Pharmaceuticals, received speaker honoraria from Nutricia, PIAM, Lansgstone Technology, GE Healthcare, Lilly, UCB Pharma and Chiesi Pharmaceuticals.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll study data, including raw and analysed data, and materials will be available from the corresponding author, A.P., upon reasonable request.